1. < Uncategorized

Bone Biopsy as a Diagnostic Pivot in a Patient with a Fracture Receiving Dialysis.  Man Kit Michael Siu¹; Lemar A. Gardezi¹; Sean Lei¹; Shilpa Sharma¹; Renata C. Pereira²; Connie Rhee¹. ¹VA Greater Los Angeles Healthcare System, Los Angeles, California, United States; ²University of California Los Angeles Department of Medicine, Los Angeles, California, United States

---

Improving Kidney Failure Risk Predictions for Clinical Trials Across CKD Stages 1-4. Leonid Shpaner¹; Panayiotis Petousis¹; Susanne B. Nicholas¹; Alex Bui¹; Obidiugwu Duru¹; Lindsey M. Kornowske²; Cami R. Jones²; Kenn B. Daratha²; Keith C. Norris¹; Katherine R. Tuttle². ¹University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States; ²Providence Health and Services, Renton, Washington, United States 

---

Dosing, Treatment Patterns, Urine Albumin-to-Creatinine Ratio (UACR) Changes, and Safety with Finerenone Treatment in Routine Care: FINE-REAL Interim Analysis. Ricardo Correa-Rotter¹; Christoph Wanner²; David C. Wheeler³; Lixin Guo⁴; Nihar Desai⁵; Sankar D. Navaneethan⁶; Susanne B. Nicholas⁷; Nan Hee Kim⁸; Jon Mares⁹; Maria Sonia Ares Gomez¹⁰; Andrea Horvat-Broecker¹¹; Marcel Schulze¹²; Martin Merz¹²; Kevin M. Pantalone¹³. ¹Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico; ²University Hospital Würzburg, Würzburg, Germany; 3University College London, London, United Kingdom; ⁴Chinese Academy of Medical Sciences, Bejing, China; ⁵Yale School of Medicine, New Haven, Connecticut, United States; ⁶Baylor College of Medicine, Houston, Texas, United States; ⁷David Geffen School of Medicine, University of California, Los Angeles, California, United States; ⁸Korea University College of Medicine, Seongbuk-gu, Seoul, Korea (the Republic of); ⁹Bayer US LLC, Whippany, New Jersey, United States; ¹⁰Syneos Health, Madrid, Spain; 11Bayer AG, Wuppertal, Germany; ¹²Bayer AG, Berlin, Germany; ¹³Cleveland Clinic, Cleveland, Ohio, United States 

---

TH-PO1004 — 2025 ASN    

Predicting Kidney Function Decline in American Indian and Alaska Native Populations with Diabetes. Anna M. Zemke¹; Kiara Mayhand²; Radica Z. Alicic¹; Lindsey M. Kornowske³; Cami R. Jones³; Kenn B. Daratha³; Christina Reynolds³; Susanne B. Nicholas⁴; Panayiotis Petousis⁴; Leonid Shpaner⁴; Joshua J. Neumiller⁵; Keith C. Norris⁴; Nisha Bansal¹; Katherine R. Tuttle¹. ¹University of Washington, Seattle, Washington, United States; ²Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States; ³Providence Health and Services, Renton, Washington, United States; ⁴University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States; ⁵Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington, United States 

---

FR-PO0889 — 2025 ASN    

Real-World Experience with Targeted-Release Budesonide in the Treatment of IgAN. Farid Arman¹; Mohammad Kamgar¹; Lama M. Abdelnour¹; Sina Emami¹; Tristan Grogan¹; Niloofar Nobakht¹. ¹University of California Los Angeles, Los Angeles, California, United States 

---

FR-PO0963 — 2025 ASN    

Living-Donor Kidney Transplantation by Insurance Coverage over Two Decades. Fawaz Al Ammary¹; Kamyar Kalantar-Zadeh²; Connie Rhee³; Suphamai Bunnapradist³; Glenda M. Flores¹; Karen D. Lincoln¹; Simeon Adeyemo¹. ¹University of California Irvine, Irvine, California, United States; ²Harbor-UCLA Medical Center, Torrance, California, United States; ³University of California Los Angeles, Los Angeles, California, United States 

---

FR-PO0620 — 2025 ASN    

A Curious Case of Chronic Hyponatremia. Lemar A. Gardezi¹; Sean Lei¹; Shaya Nikfar¹; Connie Rhee¹; Man Kit Michael Siu¹. ¹VA Greater Los Angeles Healthcare System, Los Angeles, California, United States 

---

FR-PO1123 — 2025 ASN    

Growth Differentiation Factor 15, Survival, and Hospitalization in a National Dialysis Cohort. Connie Rhee¹; Seungsook You¹; Steven M. Brunelli²; Yoko Narasaki¹; Michael P. Duggan¹; Peter Horvath³; Andrea C. Daza Aguilar¹; Man Kit Michael Siu¹; Danh V. Nguyen³; Kamyar Kalantar-Zadeh¹. ¹University of California Los Angeles, Los Angeles, California, United States; ²DaVita Inc, Denver, Colorado, United States; ³University of California Irvine, Irvine, California, United States 

---

FR-PO0338 — 2025 ASN    

Risk of Kidney Failure by Diagnosis and Histology in Diabetes. Katherine R. Tuttle¹; Lindsey M. Kornowske¹; Jonathan E. Zuckerman²; Leonid Shpaner²; Panayiotis Petousis²; Cynthia C. Nast³; Susanne B. Nicholas²; Keith C. Norris²; Cami R. Jones¹; Chakradhari Inampudi⁴; Kenn B. Daratha¹; Marino A. Bruce⁵; Radica Z. Alicic¹. ¹Providence Health and Services, Spokane, Washington, United States; ²University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States; ³Cedars-Sinai, Los Angeles, California, United States; ⁴Medical University of South Carolina, Charleston, South Carolina, United States; ⁵University of Houston System, Houston, Texas, United States 

---

SA-PO0772 — 2025 ASN    

Real-World (RW) Insights on How Health Care Providers (HCPs) Define Glomerular Inflammation in IgAN in the United States (US). Helen Trenz¹; Briana C. Ndife¹; Titte Srinivas¹; Ruth Haile-Meskale¹; Irina Pivneva²; Marie Louise Edwards²; Annika Anderson²; Sinia Sareen²; James Signorovitch²; Anjay Rastogi^{3 1}Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States; ²Analysis Group Inc Boston, Boston, Massachusetts, United States; ³University of California Los Angeles, Los Angeles, California, United States 

---

SA-PO0774 — 2025 ASN    

Real-World (RW) Clinical Considerations for IgAN Treatment Decisions: Survey of Health Care Providers (HCPs) in the United States (US). Briana C. Ndife¹; Helen Trenz¹; Titte Srinivas1; Ruth Haile-Meskale¹; Irina Pivneva2; Marie Louise Edwards²; Annika Anderson²; Kaitlyn Easson²; James Signorovitch²; Anjay Rastogi³. ¹Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States; ²Analysis Group Inc Boston, Boston, Massachusetts, United States; ³University of California Los Angeles, Los Angeles, California, United States 

---

SA-PO0799 — 2025 ASN    

Real-World Data on Voclosporin for the Treatment of Lupus Nephritis, Including Use of Concomitant Biologic Therapies: Analysis of the Enlight-LN Registry.  Mohammad Kamgar¹; Niloofar Nobakht¹; Laura B. Geraldino-Pardilla²; Leanna M. Wise³; Amber Rosales⁴; Barbara McIntosh⁴; Ronald P. Flauto^{4  1}University of California Los Angeles, Los Angeles, California, United States; ²Columbia University, New York, New York, United States; ³University of Southern California, Los Angeles, California, United States; ⁴Aurinia Pharmaceuticals Inc, Rockville, Maryland, United States 

---

SA-PO0889 — 2025 ASN    

Real-World Data on Low Proteinuria with Sparsentan (SPAR) in Patients (Pts) with IgAN: A Case Series.  Raymond K. Hsu¹; Grace Choi²; Christie H. Izutsu³; Mohammad Kamgar⁴; Niloofar Nobakht⁴; Basmina Parmakhtiar⁵; Agness Pelts Block⁵; Nasim Wiegley⁶. ¹University of California, San Francisco, California, United States; ²Cedars-Sinai Health System, Los Angeles, California, United States; ³University of Hawaii, Honolulu, Hawaii, United States; ⁴University of California, Los Angeles, California, United States; ⁵Travere Therapeutics, Inc., San Diego, California, United States; ⁶University of California, Davis, Sacramento, California, United States

---